Literature DB >> 11602786

Movements of vaccinia virus intracellular enveloped virions with GFP tagged to the F13L envelope protein.

María M Geada1, Inmaculada Galindo1, María M Lorenzo1, Beatriz Perdiguero1, Rafael Blasco1.   

Abstract

Vaccinia virus produces several forms of infectious virions. Intracellular mature virions (IMV) assemble in areas close to the cell nucleus. Some IMV acquire an envelope from intracellular membranes derived from the trans-Golgi network, producing enveloped forms found in the cytosol (intracellular enveloped virus; IEV), on the cell surface (cell-associated enveloped virus) or free in the medium (extracellular enveloped virus; EEV). Blockage of IMV envelopment inhibits transport of virions to the cell surface, indicating that enveloped virus forms are required for virion movement from the Golgi area. To date, the induction of actin tails that propel IEV is the only well-characterized mechanism for enveloped virus transport. However, enveloped virus transport and release occur under conditions where actin tails are not formed. In order to study these events, recombinant vaccinia viruses were constructed with GFP fused to the most abundant protein in the EEV envelope, P37 (F13L). The P37-GFP fusion, like normal P37, accumulated in the Golgi area and was incorporated efficiently into enveloped virions. These recombinants allowed the monitoring of enveloped virus movements in vivo. In addition to a variety of relatively slow movements (<0.4 microm/s), faster, saltatory movements both towards and away from the Golgi area were observed. These movements were different from those dependent on actin tails and were inhibited by the microtubule-disrupting drug nocodazole, but not by the myosin inhibitor 2,3-butanedione monoxime. Video microscopy (5 frames per s) revealed that saltatory movements had speeds of up to, and occasionally more than, 3 microm/s. These results suggest that a second, microtubule-dependent mechanism exists for intracellular transport of enveloped vaccinia virions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602786     DOI: 10.1099/0022-1317-82-11-2747

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  51 in total

1.  Identification of second-site mutations that enhance release and spread of vaccinia virus.

Authors:  Ehud Katz; Elizabeth Wolffe; Bernard Moss
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  Investigation of structural and functional motifs within the vaccinia virus A14 phosphoprotein, an essential component of the virion membrane.

Authors:  Jason Mercer; Paula Traktman
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

3.  Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative.

Authors:  Barbara Müller; Jessica Daecke; Oliver T Fackler; Matthias T Dittmar; Hanswalter Zentgraf; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

4.  The A33-dependent incorporation of B5 into extracellular enveloped vaccinia virions is mediated through an interaction between their lumenal domains.

Authors:  Winnie M Chan; Brian M Ward
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

5.  There is an A33-dependent mechanism for the incorporation of B5-GFP into vaccinia virus extracellular enveloped virions.

Authors:  Winnie M Chan; Brian M Ward
Journal:  Virology       Date:  2010-04-07       Impact factor: 3.616

6.  The pseudorabies virus VP1/2 tegument protein is required for intracellular capsid transport.

Authors:  G W Gant Luxton; Joy I-Hsuan Lee; Sarah Haverlock-Moyns; Joseph Martin Schober; Gregory Allan Smith
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

7.  A trans-Golgi network resident protein, golgin-97, accumulates in viral factories and incorporates into virions during poxvirus infection.

Authors:  Dina Alzhanova; Dennis E Hruby
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

8.  Studies of ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha.

Authors:  Akihito Yonezawa; Marielle Cavrois; Warner C Greene
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

9.  Loss of cytoskeletal transport during egress critically attenuates ectromelia virus infection in vivo.

Authors:  Helena Lynn; Jacquelyn Horsington; Lee Kuan Ter; Shuyi Han; Yee Lian Chew; Russell J Diefenbach; Michael Way; Geeta Chaudhri; Gunasegaran Karupiah; Timothy P Newsome
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

10.  The vaccinia virus F13L YPPL motif is required for efficient release of extracellular enveloped virus.

Authors:  Kady M Honeychurch; Guang Yang; Robert Jordan; Dennis E Hruby
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.